Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease
- PMID: 20930090
- PMCID: PMC3052227
- DOI: 10.2215/CJN.04560510
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease
Abstract
Background and objectives: Experimental studies suggest a detrimental role for vasopressin in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, it is unknown whether endogenous vasopressin concentration is associated with disease severity in patients with ADPKD.
Design, setting, participants, & measurements: Plasma copeptin concentration (a marker of endogenous vasopressin levels) was measured in 102 ADPKD patients (diagnosis based on Ravine criteria) by an immunoassay. Plasma and urinary osmolarity were also measured. To assess disease severity, GFR and effective renal blood flow were measured by continuous infusion of 125I-iothalamate and 131I-hippuran, total renal volume by magnetic resonance imaging, and 24-hour urinary albumin excretion by nephelometry.
Results: In these ADPKD patients, copeptin was associated with the various markers of disease severity in ADPKD (positively with total renal volume [R=0.47] and albuminuria [R=0.39] and negatively with GFR [R=-0.58] and effective renal blood flow [R=-0.52], all P<0.001). These associations were independent of age, gender, and use of diuretics. Copeptin was furthermore associated with plasma osmolarity (P<0.001) but not with 24-hour urinary volume, 24-hour urinary osmolarity or fractional urea excretion (P=0.7, 0.9, and 0.3, respectively).
Conclusions: On cross-sectional analysis, copeptin is associated with disease severity in ADPKD patients, supporting the results of experimental studies that suggest that vasopressin antagonists have a renoprotective effect in ADPKD and offering a good prospect for clinical studies with these agents.
Figures


Similar articles
-
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19. Clin J Am Soc Nephrol. 2012. PMID: 22516290
-
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).Clin Exp Nephrol. 2015 Dec;19(6):1199-205. doi: 10.1007/s10157-015-1101-7. Epub 2015 Feb 27. Clin Exp Nephrol. 2015. PMID: 25715868
-
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 2012 Nov;27(11):4131-7. doi: 10.1093/ndt/gfs070. Epub 2012 Apr 20. Nephrol Dial Transplant. 2012. PMID: 22523115
-
Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?World J Nephrol. 2018 Mar 6;7(2):51-57. doi: 10.5527/wjn.v7.i2.51. World J Nephrol. 2018. PMID: 29527508 Free PMC article. Review.
-
Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.Minerva Med. 2015 Feb;106(1):53-64. Epub 2014 Oct 10. Minerva Med. 2015. PMID: 25300895 Review.
Cited by
-
Vasopressin and Copeptin in health and disease.Rev Endocr Metab Disord. 2019 Sep;20(3):283-294. doi: 10.1007/s11154-019-09509-9. Rev Endocr Metab Disord. 2019. PMID: 31656992 Review.
-
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.J Am Soc Nephrol. 2014 Jun;25(6):1140-7. doi: 10.1681/ASN.2013101037. Epub 2014 Feb 20. J Am Soc Nephrol. 2014. PMID: 24556353 Free PMC article. Review.
-
Identification of Biomarkers for PKD1 Using Urinary Exosomes.J Am Soc Nephrol. 2015 Jul;26(7):1661-70. doi: 10.1681/ASN.2014040354. Epub 2014 Dec 4. J Am Soc Nephrol. 2015. PMID: 25475747 Free PMC article.
-
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22. Am J Kidney Dis. 2013. PMID: 23089511 Free PMC article.
-
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10. PLoS One. 2013. PMID: 23326375 Free PMC article.
References
-
- Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 81: 289–298, 1995 - PubMed
-
- Peters DJ, Spruit L, Saris JJ, Ravine D, Sandkuijl LA, Fossdal R, Boersma J, van ER, Norby S, Constantinou-Deltas CD: Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 5: 359–362, 1993 - PubMed
-
- Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332–342, 1993 - PubMed
-
- Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287–1301, 2007 - PubMed
-
- Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372–390, 2001 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources